Alcohol Withdrawal Craving Treatment with Low Dose of Buprenorphine: A New ExperienceJamshid Ahmadi*
Founding Director, Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
- *Corresponding Author:
- Jamshid Ahmadi
Professor and Founding Director
Substance Abuse Research Center
Shiraz University of Medical Sciences, Shiraz, Iran
E-mail: [email protected]
Received Date: August 08, 2016; Accepted Date: September 24, 2016; Published Date: September 29, 2016
Citation: Ahmadi J (2016) Alcohol Withdrawal Craving Treatment with Low Dose of Buprenorphine: A New Experience. J Psychiatry 19:387. doi:10.4172/2378-5756.1000387
Copyright: © 2016 Ahmadi J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Although alcohol use disorders and induced disorders are common in the world, however, only few medications, naltrexone, acamprosate, disulfiram, topiramate and baclofen are recommended for the reduction and cessation of alcohol withdrawal craving. Therefore it is required to develop new medications. Objective: To test the efficacy of low dose of buprenorphine on the reduction or cessation of alcohol withdrawal craving. Method: To evaluate the competence of four mg of buprenorphine in the treatment of alcohol craving in a case. Results: Buprenorphine administration was associated with ending of alcohol craving. In addition, buprenorphine was well endured. Discussion: Our findings demonstrated that buprenorphine has fast-acting and sustained anti-alcohol craving properties. This effect should be replicated in randomized, double-blind, placebo-controlled trials. Conclusion: To our understanding obvious effect of buprenorphine in this condition has not been issued yet.